Patents Assigned to The United States of America, as represented by the Secretary, Department of Health and Human Serv
-
Publication number: 20180086812Abstract: The invention provides a polypeptide comprising a single domain CD4, as well as a fusion protein comprising the single domain CD4 and one or more fusion partners. A nucleic acid encoding the polypeptide or fusion protein, as well as compositions or cells comprising the polypeptide, fusion protein, or nucleic acid also are provided.Type: ApplicationFiled: October 16, 2017Publication date: March 29, 2018Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Dimiter S. Dimitrov, Weizao Chen, Prabakaran Ponraj
-
Publication number: 20180071284Abstract: Disclosed are methods of preventing or treating a viral infection of a host, the method comprising administering to the host an effective amount of an inhibitor of the histone methyltransferase activity of EZH1 or EZH2. In one embodiment, the method comprises administering to the host an effective amount of a compound of Formula (I): wherein X1, X2, R1, R2, and R3 are defined herein; or pharmaceutically acceptable salts, solvates, or stereoisomers thereof. In another embodiment, the present invention provides a method of inhibiting an EZH1 or EZH2 methyltransferase in a virus-infected host, the method comprising administering to the host an effective amount of a compound of Formula (I) as defined above. In another embodiment, the present invention provides a method of improving the therapeutic effect of a pharmaceutical composition, the method comprising adding to the pharmaceutical composition a compound of Formula (I) as defined above.Type: ApplicationFiled: November 1, 2017Publication date: March 15, 2018Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Thomas M. Kristie, Jesse H. Arbuckle
-
Publication number: 20180055925Abstract: A particle construct is disclosed that includes a synthetic core with a solid surface coated with a lipid bilayer, SpoVM adhered to the lipid bilayer; and SpoIVA adsorbed to the SpoVM. In additional embodiments, an agent of interest can be covalently linked to the SpoIVA. In specific, non-limiting examples, the agent of interest is an enzyme, a detectable marker, a pharmaceutical compound, an immunosuppressant or a vaccine. Methods of using the particle constructs are disclosed, such as for treating infections, treating a tumor, delivering a vaccine, treating an autoimmune disorder or ameliorating an allergic reaction. Method are also disclosed for degrading an environmental pollutant. Methods are also disclosed for producing these particle constructs.Type: ApplicationFiled: August 7, 2015Publication date: March 1, 2018Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Kumaran S. Ramamurthi, I-Lin Wu
-
Publication number: 20180044741Abstract: Probes and primers are disclosed for detecting EBOV nucleic acid in a sample. Methods are also disclosed that utilize these probes and primers, wherein the methods can be used to detect an EBOV in a sample to identify a subject with an EBOV infection.Type: ApplicationFiled: February 18, 2016Publication date: February 15, 2018Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Ute Stroeher, Tara Sealy, Jonathan Towner, Stuart Nichol, César Albariño
-
Publication number: 20180043035Abstract: Disclosed are adeno-associated virus (AAV) vectors comprising a nucleotide sequence encoding RP2 or RPGR-ORF15 and related pharmaceutical compositions. Also disclosed are methods of treating or preventing X-linked retinitis pigmentosa, increasing photoreceptor number in a retina of a mammal, and increasing visual acuity of a mammal using the vectors and pharmaceutical compositions.Type: ApplicationFiled: March 11, 2016Publication date: February 15, 2018Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Zhijian Wu, Anand Swaroop, Suddhasil Mookherjee, Suja Hiriyanna, Tiansen Li
-
Publication number: 20180028644Abstract: Methods of thermally inactivating a rotavirus are provided according to the present invention which include exposing the rotavirus to a temperature in the range of about 50° C.-80° C., inclusive, for an incubation time sufficient to render the rotavirus incapable of replication or infection. The thermally inactivated rotavirus is antigenic and retains a substantially intact rotavirus particle structure. Vaccine compositions and methods of vaccinating a subject against rotavirus are provided which include generation and use of thermally inactivated rotavirus.Type: ApplicationFiled: October 4, 2017Publication date: February 1, 2018Applicant: The united States of America, as represented by the Secretary, Department of Health and Human ServInventors: Baoming Jiang, Roger I. Glass, Jean-Francois Saluzzo
-
Publication number: 20180030018Abstract: Methods for treating a tumor, such as a benign or malignant tumor, are disclosed herein. The methods include administering a therapeutically effective amount of a small molecule that selectively binds to and stabilizes G-quadruplex DNA in the promoter of the c-MYC gene to the subject. The methods are also of use to decrease the size and/or number of metastases. Compounds for use in the disclosed methods are also provided.Type: ApplicationFiled: January 5, 2016Publication date: February 1, 2018Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Serv, Yale UniversityInventors: John Schneekloth, JR., John Simmons, Kenneth Felsenstein, Beverly Mock, Lindsey Saunders, Peter Gareiss, David Calabrese, Elena Leon
-
Publication number: 20180016307Abstract: The invention provides modified griffithsin polypeptides comprising the amino acid sequence of SEQ ID NO: 1, as well as corresponding nucleic acids, vectors, cells, fusion proteins, constructs, conjugates, and methods of inhibiting viral infection.Type: ApplicationFiled: February 10, 2016Publication date: January 18, 2018Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Serv, University of Louisville Research Foundation, Inc., University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Barry R. O'Keefe, Tinoush Moulaei, Kenneth E. Palmer, Lisa C. Rohan, Joshua L. Fuqua, Lindsay F. Kramzer
-
Publication number: 20180015086Abstract: The invention provides methods of treating or preventing malaria comprising administering to an animal an effective amount of a compound of formula I: Q—Y—R1—R2??(I), wherein Q, Y, R1, and R2 are as described herein. Methods of inhibiting a plasmodial surface anion channel of a parasite in an animal are also provided. The invention also provides pharmaceutical compositions comprising a compound represented by formula I in combination with any one or more compounds represented by formulas II, V, and VI. Use of the pharmaceutical compositions for treating or preventing malaria or for inhibiting a plasmodial surface anion channel in animals including humans are also provided. Also provided by the invention are clag3 amino acid sequences and related nucleic acids, vectors, host cells, populations of cells, antibodies, and pharmaceutical compositions.Type: ApplicationFiled: October 3, 2017Publication date: January 18, 2018Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventor: Sanjay A. Desai
-
Publication number: 20180002675Abstract: Compositions and methods including and related to the Ebola Bundibugyo virus (EboBun) are provided. Compositions are provided that are operable as immunogens to elicit and immune response or protection from EboBun challenge in a subject such as a primate. Inventive methods are directed to detection and treatment of EboBun infection.Type: ApplicationFiled: August 28, 2017Publication date: January 4, 2018Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Jonathan S. Towner, Stuart T. Nichol, James A. Comer, Thomas G. Ksiazek, Pierre E. Rollin
-
Publication number: 20170369558Abstract: Monoclonal neutralizing antibodies are disclosed that specifically bind to the CD4 binding site of HIV-1 gp120. Monoclonal neutralizing antibodies also are disclosed that specifically bind to HIV-1 gp41. The identification of these antibodies, and the use of these antibodies are also disclosed. Methods are also provided for enhancing the binding and neutralizing activity of any antibody using epitope scaffold probes.Type: ApplicationFiled: July 27, 2017Publication date: December 28, 2017Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Serv, University of WashingtonInventors: John Mascola, Richard Wyatt, Xueling Wu, Yuxing Li, Carl-Magnus Hogerkorp, Mario Roederer, Zhi-yong Yang, Gary Nabel, Peter Kwong, Tongqing Zhou, Mark Connors, William Schief
-
Publication number: 20170340640Abstract: Adenosine kinase inhibitors, including pharmaceutical compositions containing the adenosine kinase inhibitors, and their use for preventing epilepsy and its progression in patients. The adenosine kinase inhibitors have the formula: where the moieties J and K, considered in combination, are —CH2—, or K and L, considered in combination, are —CH2—. The R1 moiety can be —NH2, C1-C6 alkyl, C1-C6 alkoxy, or C1-C6 hydroxyalkyl. The R2 and R3 moieties are each independently C1-C6 alkyl. The R4 moiety is hydrogen or C1-C6 alkyl. The R5 and R6 moieties are each independently C6-C12 aryl, C3-C8 cycloalkyl, or C3-C8 heteroaryl, that is optionally further substituted.Type: ApplicationFiled: May 26, 2017Publication date: November 30, 2017Applicants: Legacy Emanuel Hospital & Health Center, The United States of America, as represented by The Secretary, Department of Health and Human ServInventors: Kenneth Alan Jacobson, Detlev Boison, Kiran Shambhu Toti
-
Publication number: 20170319643Abstract: Described herein is the design and construction of a class of lipoprotein targeting protease inhibitors. Small peptides with protease inhibitor activity are conjugated to hydrophobic, lipoprotein targeting molecules using, for instance, amine reactive chemistry. Methods of use of the resultant lipoprotein targeting protease inhibitor (antiprotease) molecules are also described. Also described is the production and use of protease inhibitor enriched HDL particles, as well as A1AT-peptide-enriched HDL particles, and their use in various therapeutic contexts.Type: ApplicationFiled: October 18, 2016Publication date: November 9, 2017Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Alan T. Remaley, Scott M. Gordon
-
Publication number: 20170304420Abstract: The invention relates to an adjuvant comprising Pattern Recognition Receptor (PRR) agonist molecules linked to polymer chains that are capable of undergoing particle formation in aqueous conditions, or in aqueous conditions in response to external stimuli; and methods of treatment or prevention of disease using such an adjuvant.Type: ApplicationFiled: October 9, 2015Publication date: October 26, 2017Applicants: Oxford University Innovation Limited, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVInventors: Kerry Fisher, Richard Laga, Geoffrey Lynn, Leonard Seymour, Robert Seder
-
Publication number: 20170305904Abstract: A method of inhibiting drug-resistant HIV-1 integrase in a subject comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or ester thereof, having a structure of: wherein X is N, C(OH), or CH; Y is H or OH; each of Z1-Z5 is independently H or halogen; R4 is H, OH, NH2, NHR8, NR8R9 or R8; R5, R6, and R7 is each independently H, halogen, OR8, R8, NHR8, NR8R9, CO2R8, CONR8R9, SO2NR8R9, or R5 and R6 together with the carbon atoms to which R5 and R6 are attached form an optionally-substituted carbocycle or optionally-substituted heterocycle; and R8 and R9 is each independently H, optionally-substituted alkyl, optionally-substituted alkenyl, optionally-substituted alkynyl, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted cycloalkylene, optionally-substituted heterocycle, optionally-substituted amide, optionally-substituted ester, or R8 and R9 together with the nitrogen tType: ApplicationFiled: May 8, 2017Publication date: October 26, 2017Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Xue Zhi Zhao, Steven Smith, Mathieu Metifiot, Barry Johnson, Christophe Marchand, Stephen H. Hughes, Yves Pommier, Terrence R. Burke, JR.
-
Publication number: 20170306042Abstract: The invention is directed to methods of reducing growth of prostate cancer cells and breast cancer cells, which comprises treating such cancer cells with a combination of androgen or endocrine deprivation therapy (e.g., enzalutamide, abiraterone, and tamoxifen) and immunotherapy.Type: ApplicationFiled: August 28, 2015Publication date: October 26, 2017Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Jeffrey Schlom, James W. Hodge
-
Publication number: 20170298101Abstract: Disclosed are immunogens including a recombinant RSV F protein stabilized in a prefusion conformation. Also disclosed are nucleic acids encoding the immunogens and methods of producing the immunogens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the immunogen to the subject.Type: ApplicationFiled: June 26, 2017Publication date: October 19, 2017Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Peter Kwong, Barney Graham, Jason McLellan, Man Chen, Baoshan Zhang, Tongqing Zhou
-
Publication number: 20170267748Abstract: Monoclonal neutralizing antibodies that specifically bind to HIV-1 gp120 and antigen binding fragments of these antibodies are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV infection is disclosed.Type: ApplicationFiled: June 2, 2017Publication date: September 21, 2017Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Peter D. Kwong, Gary J. Nabel, Rebecca S. Rudicell, John Mascola, Mark Connors, Ivelin Georgiev, Jiang Zhu, Young Do Kwon, Tongqing Zhou, Yongping Yang, Baoshan Zhang, Gwo-Yu Chuang, Xueling Wu, Zhi-yong Yang, Wei Shi
-
Publication number: 20170258847Abstract: The invention generally relates to postnatal dental stem cells and methods for their use. More specifically, the invention relates in one aspect to postnatal dental pulp stem cells, use of the cells to generate dentin, and differentiation of the cells. In another aspect, the invention relates to human postnatal deciduous dental pulp multipotent stem cells, use of the cells to generate dentin, and differentiation of the cells.Type: ApplicationFiled: May 19, 2017Publication date: September 14, 2017Applicant: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human ServInventors: Songtao Shi, Pamela Gehron Robey, Stan Gronthos, Masako Miura
-
Publication number: 20170252396Abstract: Methods for treating pancreatic cancer via administration of small anti-inflammatory peptides. The peptides may be administered in conjunction with another therapeutic agent or therapeutic regimen.Type: ApplicationFiled: October 13, 2015Publication date: September 7, 2017Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Serv, Riptide Bioscience, Inc.Inventors: Udo Rudloff, Jesse M. Jaynes, Henry W. Lopez, George R. Martin, Clayton Yates